The correlation of circulating miR-29b and inflammatory markers with albuminuria in hypertensive patients

References

• Mennuni S, Rubattu S, Pierelli G, Tocci G, Fofi C, Volpe M. Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage. J Hum Hypertens. 2014;28(2):74–79. doi:10.1038/jhh.2013.55.
   PubMed Web of Science ®Google Scholar
• Tylicki L, Rutkowski B. [Hypertensive nephropathy: pathogenesis, diagnosis and treatment]. Pol Merkur Lekarski. 2003;14(80):168–73.
   PubMedGoogle Scholar
• Zucchelli P, Zuccala A. Hypertension and renal dysfunction. Curr Opin Nephrol Hypertens. 1996;5(1):97–101. doi:10.1097/00041552-199601000-00016.
   PubMedGoogle Scholar
• Stoian M, State N, Stoica V, Radulian G. Albuminuria–marker of progressive renal disease. J Med Life. 2012;5(4):420–22.
   PubMedGoogle Scholar
• Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. doi:10.1093/eurheartj/eht151.
   PubMed Web of Science ®Google Scholar
• Tian D, Ling S, Chen G, Li Y, Liu J, Ferid M, Bian K. Hypertensive nephropathy treatment by heart-protecting musk pill: a study of anti-inflammatory therapy for target organ damage of hypertension. Int J Gen Med. 2011;4:131–39.
   PubMedGoogle Scholar
• Seccia TM, Caroccia B, Calo LA. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J Hypertens. 2017;35(2):205–12. doi:10.1097/HJH.0000000000001170.
   PubMed Web of Science ®Google Scholar
• Wu Y, Potempa LA, El KD, Filep JG. C-reactive protein and inflammation: conformational changes affect function. Biol Chem. 2015;396(11):1181–97. doi:10.1515/hsz-2015-0149.
   PubMed Web of Science ®Google Scholar
• Kajdaniuk D, Marek B, Borgiel-Marek H, Kos-Kudla B. Transforming growth factor beta1 (TGFbeta1) in physiology and pathology. Endokrynol Pol. 2013;64(5):384–96.
   PubMed Web of Science ®Google Scholar
• Young B, Gleeson M, Cripps AW. C-reactive protein: a critical review. Pathology. 1991;23(2):118–24. doi:10.3109/00313029109060809.
   PubMed Web of Science ®Google Scholar
• Zhu S, Liu Y, Wang L, Meng QH. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker. Nephrol Dial Transplant. 2008;23(9):2841–46. doi:10.1093/ndt/gfn159.
   PubMed Web of Science ®Google Scholar
• Herman-Edelstein M, Weinstein T, Gafter U.TGFbeta1-dependent podocyte dysfunction. Curr Opin Nephrol Hypertens. 2013;22(1):93–99. doi:10.1097/MNH.0b013e32835b4870.
   PubMed Web of Science ®Google Scholar
• Cirillo F, Lazzeroni P, Catellani C, Sartori C, Amarri S, Street ME. MicroRNAs link chronic inflammation in childhood to growth impairment and insulin-resistance. Cytokine Growth Factor Rev. 2018;39:1–18. doi:10.1016/j.cytogfr.2017.12.004.
   PubMed Web of Science ®Google Scholar
• Synetos A, Toutouzas K, Stathogiannis K, Latsios G, Tsiamis E, Tousoulis D, Stefanadis C. MicroRNAs in arterial hypertension. Curr Top Med Chem. 2013;13(13):1527–32. doi:10.2174/15680266113139990101.
   PubMed Web of Science ®Google Scholar
• Barwari T, Joshi A, Mayr M.MicroRNAs in cardiovascular disease. J Am Coll Cardiol. 2016;68(23):2577–84. doi:10.1016/j.jacc.2016.09.945.
   PubMed Web of Science ®Google Scholar
• Wang B, Komers R, Carew R, Winbanks CE, Xu B, Herman-Edelstein M, Koh P, Thomas M, Jandeleit-Dahm K, Gregorevic P, et al. Suppression of microRNA-29 expression by TGF-beta1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol. 2012;23(2):252–65. doi:10.1681/ASN.2011010055.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang XR, Wei LH, Chung AC, Yu CM, Lan HY.miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol Ther. 2014;22(5):974–85. doi:10.1038/mt.2014.25.
   PubMed Web of Science ®Google Scholar
• Liu LS. [2010 Chinese guidelines for the management of hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2011;39(7):579–615.
   PubMedGoogle Scholar
• Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL,  Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30):10513–18. doi:10.1073/pnas.0804549105.
   PubMed Web of Science ®Google Scholar
• Huang Y, Chen J, Zhou Y, Tang S, Li J, Yu X, Mo Y, Wu Y, Zhang Y, Feng Y, et al. Circulating miR155 expression level is positive with blood pressure parameters: potential markers of target-organ damage. Clin Exp Hypertens. 2016;38(3):331–36. doi:10.3109/10641963.2015.1116551.
   PubMed Web of Science ®Google Scholar
• Kang K, Zhang X, Liu H, Wang Z, Zhong J, Huang Z, Peng X, Zeng Y, Wang Y, Yang Y, Luo J, Gou DM. A novel real-time PCR assay of microRNAs using S-Poly(T), a specific oligo(dT) reverse transcription primer with excellent sensitivity and specificity. PLoS One 2012;7:e48536.
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Nopel-Dunnebacke S, Ahrens M, Jensen SG, Zollner H, Maghnouj A, Wos A, Mayerle J, Munding J, Kost D, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer. 2013;132(2):E48–57. doi:10.1002/ijc.27791.
   PubMed Web of Science ®Google Scholar
• Association AD. Standards of medical care in diabetes–2013. Diabetes Care. 2013;36(Suppl 1):S11–66.
   PubMedGoogle Scholar
• Mihajlov R, Stoeva D, Pencheva B, Bogusheva E, Ruseva A, Gencheva-Angelova I.Albuminuria and glomerular filtration in patients with essential hypertension. Clin Lab. 2015;61(7):677–85. doi:10.7754/Clin.Lab.2014.141121.
   PubMed Web of Science ®Google Scholar
• Mehta T, Buzkova P, Kizer JR, Djousse L, Chonchol M, Mukamal KJ, Shlipak M, Ix JH, Jalal D. Higher plasma transforming growth factor (TGF)-beta is associated with kidney disease in older community dwelling adults. BMC Nephrol 2017;18:98.
   PubMed Web of Science ®Google Scholar
• Ghayur A, Margetts PJ.Transforming growth factor-beta and the glomerular filtration barrier. Kidney Res Clin Pract. 2013;32(1):3–10. doi:10.1016/j.krcp.2013.01.003.
   PubMedGoogle Scholar
• Tang PM, Zhang YY, Mak TS, Tang PC, Huang XR, Lan HY. TGF-beta signalling in renal fibrosis: from Smads to non-coding RNAs. J Physiol. 2018. doi:10.1113/JP274492.
   Web of Science ®Google Scholar
• Lan HY, Chung AC. Transforming growth factor-beta and Smads. Contrib Nephrol. 2011;170:75–82.
   PubMed Web of Science ®Google Scholar
• Lan HY. Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. Int J Biol Sci. 2011;7(7):1056–67.
   PubMed Web of Science ®Google Scholar
• Chen J, Du L, Li J, Song H. Epigallocatechin-3-gallate attenuates cadmium-induced chronic renal injury and fibrosis. Food Chem Toxicol. 2016;96:70–78. doi:10.1016/j.fct.2016.07.030.
   PubMed Web of Science ®Google Scholar
• Gyorfi AH, Matei AE, Distler J. Targeting TGF-beta signaling for the treatment of fibrosis. Matrix Biol. 2018;68-69:8–27. doi:10.1016/j.matbio.2017.12.016.
   PubMed Web of Science ®Google Scholar
• Hsu YC, Chang PJ, Ho C, Huang YT, Shih YH, Wang CJ, Lin CL. Protective effects of miR-29a on diabetic glomerular dysfunction by modulation of DKK1/Wnt/beta-catenin signaling. Sci Rep. 2016;6:30575.
   PubMed Web of Science ®Google Scholar